VELCADE
information and resources from the National Cancer Institute
VELCADE
(Other name for: bortezomib)Velsar
(Other name for: vinblastine)VELCADE
(Other name for: bortezomib)
|
|
|
|
news articles
Cancer patient to get free drug 01 Apr 2006
Globe and Mail, ...therapeutic alternatives available on the market.�?. Actually, there is a licensed alternative called Velcade. It is used to treat ...
Infinity Announces Three Leadership Promotions Mar 30, 2006
Yahoo! News (press release) ...brought with him a track record of successfully discovering and developing several first-in-class agents including, most recently, Velcade®, a proteasome ...
Velcade Lung Cancer Study Begins Mar 6, 2006
TheStreet.com ...and its partner Johnson & Johnson (JNJ:NYSE - commentary - research - Cramer's Take) have started trials to examine the multiple myeloma drug Velcade as a ...
Millennium Pharmaceuticals: more Velcade ventures Mar 7, 2006
Pharmaceutical Business Review Millennium Pharmaceuticals and Johnson & Johnson have initiated a phase II trial of Velcade in combination with pemetrexed in non small lung cancer (NSCLC). ...
Updated Results with Velcade® in Multiple Myeloma Mar 3, 2006
Cancer Consultants (press release), According to results recently published in the journal Cancer, updated results from a clinical trial evaluating Velcade® (bortezomib) in the treatment of ...
Panel proposes NIS 466 million for new subsidized medicines Mar 29, 2006
Ha'aretz, The new medications include: Herceptin for breast cancer, Velcade for bone marrow cancer, a growth hormone for treating abnormally short children and a new ...
Why use free drug when you can pay $35,000? Mar 22, 2006
Globe and Mail, ...will provide at no cost under its compassionate-use program, there's no way Mr. Bouchard, 73, can afford the licensed alternative, Velcade, to treat his ...
CuraGen and TopoTarget Announce Initiation of First NCI-sponsored ... Mar 29, 2006
Yahoo! News (press release) ...evaluating the safety and tolerability of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with bortezomib (Velcade®) for the ...
TopoTarget and CuraGen announce initiation of first NCI-sponsored ... Mar 29, 2006
PharmaLive.com (press release), ...sponsored by the US National Cancer Institute (NCI) and will evaluate the safety and tolerability of PXD101 in combination with bortezomib (Velcade®) for the ...
CuraGen and TopoTarget Announce Initiation of First NCI-sponsored ... Mar 29, 2006
PR Newswire (press release), ...- Phase I trial to evaluate PXD101 plus bortezomib (Velcade(R)) for the treatment of ... Velcade(R) is a registered trademark of Millennium Pharmaceuticals, Inc. ...
CuraGen and TopoTarget Initiate Phase Ib/II Clinical Trial with ... Mar 22, 2006
PR Newswire (press release), ...in a Phase Ib/II proof-of-concept trial to evaluate PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with Velcade(R) (bortezomib ...
Millennium and Johnson & Johnson Pharmaceutical Research & ... Mar 6, 2006
PR Newswire (press release), Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD), the initiation of a three-arm, randomized, Phase II study of VELCADE and pemetrexed in ...
Ottawa's stand on drugs 'completely unacceptable' Mar 23, 2006
Globe and Mail, ..."The inability to access thalidomide and Velcade in this province will lead to the unnecessary early deaths of hundreds of patients within the next few weeks ...
Millennium Achieves $10 Million Milestone Payment Mar 9, 2006
PharmaLive.com (press release), ...a $10 million payment from Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD) based on sales milestones reached for VELCADE(R) (bortezomib ...
CuraGen And TopoTarget Start Patient Dosing In Phase Ib/II Trial ... Mar 22, 2006
Trading Markets, ...patient dosing in a Phase Ib/II proof-of-concept trial to evaluate PXD101, a small molecule histone deacetylase inhibitor, in combination with Velcade for the ...
CuraGen and TopoTarget begin cancer study Mar 24, 2006
Pharmaceutical Business Review The phase Ib/II proof-of-concept trial will examine PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with Velcade (bortezomib) for ...
Millennium CEO says may form strategic partnership Mar 10, 2006
Reuters ...including acquisitions, on the table for Millennium as it seeks to boost revenue growth amid growing competition for its cancer drug Velcade, Deborah Dunsire ...
CuraGen, TopoTarget Initiate Patient Dosing In Phase I Clinical ... Mar 29, 2006
Trading Markets, PXD101 were being conducted in parallel to those clinical trials sponsored by itself, including the Phase Ib/II study of PXD101 plus Velcade (bortezomib) for ...
Scientists Making Advances In Cancer To Receive International ... Mar 25, 2006
Medical News Today (press release), He is being honored for the synthesis of the first selective proteasome inhibitor, bortezomib (VELCADE), for recognizing the potential of a proteasome ...
Millennium And Johnson & Johnson Reveals Phase II Study Of VELCADE ... Mar 6, 2006
Trading Markets, ...and Johnson & Johnson Pharmaceutical Research & Development LLC, revealed the initiation of a three-arm, randomized, Phase II study of VELCADE and pemetrexed ...
Millennium achieves $10M milestone payment Mar 9, 2006
Boston Mass High Tech, ...receive a $10 million payment from Johnson & Johnson Pharmaceutical Research & Development LLC, based on sales milestones reached for Velcade (for injection ...
(PRN) - AsiaInfo to Announce 2006 First Quarter Results on April ... Mar 22, 2006
Bolsamania.com, ...net ... [+. PRN) - CuraGen and TopoTarget Initiate Phase Ib/II Clinical Trial with PXD101 and Velcade(R) for Multiple Myeloma ... [+. ...
Cytogen Announces Schedule for Clinical Data Presentations at ... Mar 23, 2006
PR Newswire (press release), ...that interim data will be presented from one of the first combination trials of QUADRAMET with the protease inhibitor bortezomib (Velcade(R), Millennium ...
Prescription drug purchases by Canadian hospitals and pharmacies ... Mar 15, 2006
Canada NewsWire (press release), ...with $9.4 million. Cancer medication Velcade(R) was the third leading new product with sales of $5 million. Hospital Purchases Sales ...
Kosan Reports 2005 Fourth Quarter and Year End Results Mar 2, 2006
PR Newswire (press release), 2005 Product Development Highlights Hsp90 Inhibitor Program -- Demonstration of clinical activity of KOS-953 in combination with bortezomib (Velcade(R)) in ...
Cytogen Announces Schedule for Clinical Data Presentations at ... Mar 23, 2006
Yahoo! News (press release) ...data will be presented from one of the first combination trials of QUADRAMET with the protease inhibitor bortezomib (Velcade®, Millennium Pharmaceuticals, Inc ...
This week in London Mar 6, 2006
London Free Press, Multiple Myeloma special presentation: Presentation by Kathleen Colson, Dana Farber Cancer Institute, on recent clinical trial results for Velcade, common side ...
OSI Pharma's Cancer Drug Data May Boost Stock Mar 13, 2006
Forbes ...for Tarceva in ovarian cancer and colon cancer; Samad expects future studies evaluating Tarceva as combination therapy with Erbitux, Velcade and Nexavar. ...
(PRN) - 485 Courts in Session With Tyler's INCODE Municipal Court ... Mar 6, 2006
Bolsamania.com, ...(PRN) - Millennium and Johnson & Johnson Pharmaceutical Research & Development Initiate Randomized Phase II Trial of VELCADE(R) (Bortezomib) for Injection in ...
Bio-IT Briefs Mar 9, 2006
Bio-IT World, ...a $10 million payment from Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD) based on sales milestones reached for Velcade (bortezomib) for ...
Nereus Pharmaceuticals Closes Second Tranche of $42.6 Million ... Mar 6, 2006
PR Newswire (press release), ...generation compound could significantly enhance the market for proteasome inhibitors, which has been previously established by Millennium's Velcade(R). "With ...
Lehman Brothers Ninth Annual Global Healthcare Conference to ... Mar 2, 2006
PR Newswire (press release), Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer ...
Millennium: Velcade set for cancer consolidation Dec 13, 2005
Pharmaceutical Business Review 13 Dec 2005, 16:18 GMT - Millennium Pharmaceuticals has announced updated results from a phase III trial in which single-agent Velcade achieved a median ...
Survival boosted by six months with Velcade Dec 14, 2005
Cancerfacts.com, The study from the largest randomized international study of bortezomib (VELCADE®) in relapsed myeloma were presented this week by Dr. Paul Richardson of the ...
VELCADE(R) (bortezomib) for Injection Single-Agent and Combination ... Dec 12, 2005
PR Newswire (press release), ...(Nasdaq: MLNM) today announced positive results in a broad range of multiple myeloma populations exploring the use of VELCADE alone and in combination with ...
New Data Show Median 30-Month Survival With VELCADE(R) (Bortezomib ... Dec 11, 2005
PR Newswire (press release), III APEX trial, the largest randomized study in relapsed myeloma, and the only trial to demonstrate a survival advantage for a single agent, VELCADE, in this ...
VELCADE(R) (bortezomib) for Injection Continues to Show Impressive ... Dec 12, 2005
PR Newswire (press release), ...(Nasdaq: MLNM) today announced the results from phase II studies evaluating the efficacy and safety of VELCADE in patients with aggressive and indolent ...
VELCADE (bortezomib) for Injection Continues to Show Impressive ... Dec 13, 2005
PharmaLive.com (press release), ...today announced the results from phase II studies evaluating the efficacy and safety of VELCADE in patients with aggressive and indolent subtypes of non ...
New Data on VELCADE(R) (bortezomib) for Injection to Be Presented ... Dec 6, 2005
Yahoo! News (press release) 6 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - News) today announced that data from studies of VELCADE will be featured at the ...
New Data on VELCADE(R) (bortezomib) for Injection to Be Presented ... Dec 6, 2005
Drug Newswire (press release), CAMBRIDGE, Mass. — Millennium Pharmaceuticals, Inc. (NASDAQ:MLNM) today announced that data from studies of VELCADE will be featured at the 47th Annual ...
New Data on VELCADE (bortezomib) for Injection to be Presented at ... Dec 6, 2005
PharmaLive.com (press release), ...today announced that data from studies of VELCADE will be featured at the 47th Annual Meeting of the American Society of Hematology in Atlanta, GA., December 10 ...
New Data on VELCADE(R) (bortezomib) for Injection to Be Presented ... Dec 6, 2005
PR Newswire (press release), CAMBRIDGE, Mass., Dec. 6 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (NASDAQ: MLNM) today announced that data from studies of VELCADE will be ...
Bortezomib (Velcade) and Capecitabine (Xeloda) in Combination ... Dec 9, 2005
DG News SAN ANTONIO, TX -- December 9, 2005 -- A small phase 1 study has shown that bortezomib (Velcade) used in combination with capecitabine (Xeloda) is safe and well ...
Millennium Announces Webcast of Data on VELCADE(R) (Bortezomib) ... Dec 8, 2005
PR Newswire (press release), Millennium management will discuss VELCADE data from the 47th Annual Meeting of the American Society of Hematology being held in Atlanta, GA from December 10-13 ...
Bortezomib (Velcade) Shows Strong Survival Benefit in Relapsed ... Dec 13, 2005
DG News By Bruce Sylvester. ATLANTA, GA -- December 13, 2005 -- Extended survival data from the international, Assessment of Proteasome Inhibition ...
It's Phase 3 for biotech CEO Dec 19, 2005
Bizjournals.com, ...the cutbacks, moving ahead with an aggressive plan to focus the company primarily on cancer drug development and boost sales efforts for its cancer drug Velcade ...
Consistently High Complete and Overall Response Rates in Newly ... Dec 13, 2005
PR Newswire (press release), ATLANTA, Dec. 13 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced results from studies exploring VELCADE alone, or in ...
Consistently High Complete and Overall Response Rates in Newly ... Dec 13, 2005
PharmaLive.com (press release), ...today announced results from studies exploring VELCADE alone, or in combination with other commonly used agents, for previously untreated multiple myeloma. ...
Cancer Patient Denied Vital Drug Dec 14, 2005
MedIndia, The Southampton University Hospitals NHS Trust is reported to have cancelled the first course of the anti-cancer drug Velcade for him. ...
Patient 'denied life-saving drug' Dec 13, 2005
Daily Mail - UK, His consultant recommended him for the potentially life-saving anti-cancer drug Velcade but he was shocked to discover Southampton University Hospitals NHS ...
Geron Announces Data on the Effects of Its Cancer Drug, GRN163L ... Dec 12, 2005
PharmaLive.com (press release), In a separate study using the same model, GRN163L in combination with Velcade(TM) significantly reduced tumor growth using a dose of Velcade(TM) that had no ...
Millennium--cancer drug effective in new patients Dec 13, 2005
Reuters ...(MLNM.O: Quote, Profile, Research) said on Tuesday its multiple myeloma drug Velcade, currently approved for treating patients who have undergone one or more ...
CuraGen deal produces new cancer drug data Dec 13, 2005
DrugResearcher.com, Furthermore, synergistic activity was observed when PXD101 was combined with Velcade in antiproliferative and osteoclast formation in vitro assays, and this ...
Fit, older lung cancer patients respond to chemotherapy Dec 18, 2005
St. Petersburg Times, Other nonchemotherapeutic targeted agents in the pipeline for nonsmall-cell lung cancer include Velcade (proteosome inhibitor), Thalidomide (antiangiogeogenic ...
TopoTarget and CuraGen's PXD101 Reveals Promising Side Effect ... Dec 13, 2005
PharmaLive.com (press release), Moreover, the combination of PXD101 with Velcade® (bortezomib) showed greater growth-inhibitory activity, as compared to either drug used alone, on a MM cell ...
CuraGen and TopoTarget Announce Presentation of PXD101 Phase I ... Dec 12, 2005
PharmaLive.com (press release), Moreover, the combination of PXD101 with Velcade(R) (bortezomib) showed greater growth-inhibitory activity, as compared to either drug used alone, on a ...
POST OF THE DAY Nov 23, 2005
Motley Fool ...drug company. Their expressed aspirations are to now concentrate in oncology, where they have an approved drug Velcade. It functions ...
Kosan: Drug trial results positive Dec 12, 2005
BusinessWeek One study tested KOS-953 alone, while another looked at it in conjunction with the Velcade drug made by Millennium Pharmaceuticals Inc. ...
Kosan Reports Interim Results of KOS-953 Clinical Trials in ... Dec 12, 2005
PR Newswire (press release), Data from a Phase I single-agent clinical trial and a Phase Ib combination trial of KOS-953 co-administered with bortezomib (Velcade(R)) demonstrated early ...
Kosan Initiates Phase II Clinical Trial of KOS-953 in Combination ... Dec 8, 2005
PR Newswire (press release), ...cancer reported on today, KOS-953 is also being evaluated in a Phase I single-agent and Phase Ib combination clinical trial with bortezomib (Velcade(R)) in ...
GlycoGenesys, Inc. GCS-100 Cancer Drug Candidate Subject of ... Dec 15, 2005
Genetic Engineering News, ...programmed cell death in multiple myeloma patient cells, including those refractory to traditional chemotherapies such as dexamethasone, Velcade(R), and ...
Millennium shares slip on downgrade Dec 7, 2005
BusinessWeek The analyst said Millennium's Velcade drug, a treatment for certain blood cancers, should see competition from Celgene Corp.'s Revlimid soon with that drug's ...
Man denied cancer drug because he lives in England Dec 11, 2005
Telegraph.co.uk, He is a perfect candidate for the new drug, Velcade, which is licensed for cases such as his - a third-line treatment when two others have failed. ...
Cancer focus intensifies, luring wave of capital Dec 12, 2005
MSNBC ...recently narrowed its development focus almost entirely to cancer, based on the strength of its drug pipeline and sales potential of its cancer drug Velcade. ...
(PRN) - Brookstone to Broadcast Conference Call Via Live Webcast ... Dec 12, 2005
Bolsamania.com, Web ... [+. PRN) - VELCADE(R) (bortezomib) for Injection Continues to Show Impressive Results in a Variety of Lymphomas ... [+. ...
(PRN) - PennFuture Praises House for Sending Dirty Air Bill Back ... Dec 12, 2005
Bolsamania.com, ...(PRN) - VELCADE(R) (bortezomib) for Injection Single-Agent and Combination Studies Show Positive Outcomes in a Broad Range of Multiple Myeloma Patients ... [+. ...
(PRN) - ATCT Announce the Addition of Michael Nurse to the Board ... Dec 8, 2005
Bolsamania.com, ...(PRN) - Millennium Announces Webcast of Data on VELCADE(R) (Bortezomib) for Injection From the 47th Annual Meeting of the American Society of Hematology ... ...
Results from Preclinical Studies of Gemin X's GX15-070 Presented ... Dec 12, 2005
CCNMatthews (press release), GX15-070 in the treatment of mantle cell lymphoma (MCL), both as a monotherapy and in combination with the bortezomib (Velcade ® ) proteasome inhibitor. ...
(PRN) - Mercury and Digital China Expand Strategic Alliance to ... Dec 6, 2005
Bolsamania.com, ...[+]. (PRN) - New Data on VELCADE(R) (bortezomib) for Injection to Be Presented at Upcoming American Society of Hematology Meeting ... [+. ...
Results from Preclinical Studies of Gemin X's GX15-070 Presented ... Dec 12, 2005
Business Wire (press release), ...study evaluated GX15-070 in the treatment of mantle cell lymphoma (MCL), both as a monotherapy and in combination with the bortezomib (Velcade(R)) proteasome ...
Cytogen's QUADRAMET(R) Demonstrates Broad Anticancer Activity in ... Dec 12, 2005
PR Newswire (press release), ...the presentation of preclinical data on its flagship product QUADRAMET(R) (samarium Sm-153 lexidronam) in combination with bortezomib (Velcade(R), Millennium ...
Keryx Biopharmaceuticals, Inc. Announces Oral Presentation on KRX ... Dec 8, 2005
PR Newswire (press release), Dr. Anderson's group was instrumental in the development of Velcade(R), an approved drug for MM, and Revlimid(R), a drug pending potential approval for MM. ...
Bruce A. Leicher Joins Antigenics As General Counsel Dec 13, 2005
Yahoo! News (press release) While at Millennium, he was a leader in the creation of the commercial infrastructure to launch Velcade® (bortezomib) -- the first proteasome inhibitor ...
Cytogen's QUADRAMET(R) Demonstrates Broad Anticancer Activity in ... Dec 12, 2005
Yahoo! News (press release) ...of preclinical data on its flagship product QUADRAMET® (samarium Sm-153 lexidronam) in combination with bortezomib (Velcade®, Millennium Pharmaceuticals, Inc ...
Sirtris Pharmaceuticals Hires Peter Elliott as SVP, Head of ... Nov 30, 2005
PR Newswire (press release), Vice President of Pharmacology and Development at Millennium Pharmaceuticals, Inc., where he was a co-developer of the multiple myeloma drug, Velcade(R). Prior ...
Combination of QUADRAMET(R) and Novel First-in-class Proteasome ... Nov 28, 2005
PR Newswire (press release), ...a multicenter Phase I clinical trial to investigate the use of QUADRAMET(R) (samarium Sm-153 lexidronam) in combination with bortezomib (Velcade(R), Millennium ...
Combination of QUADRAMET(R) and Novel First-in-class Proteasome ... Nov 28, 2005
Yahoo! News (press release) Phase I clinical trial to investigate the use of QUADRAMET® (samarium Sm-153 lexidronam) in combination with bortezomib (Velcade®, Millennium Pharmaceuticals ...
Multiple myeloma: NPI-0052, a compound from marine bacteria ... Nov 19, 2005
Xagena.it, ..." Proteasome inhibition is a key therapeutic target and Bortezomib ( Velcade ) was the first in a new class of compounds in multiple myeloma. ...
|
|
